SGMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sangamo Therapeutics Inc (SGMO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak technical indicators, poor financial performance, and lacks positive catalysts or strong trading signals. Additionally, the absence of recent news, congress trading data, or influential endorsements further diminishes its appeal.
The technical indicators for SGMO are bearish. The MACD histogram is negative and contracting, RSI is neutral at 37.413, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels show the stock trading below the pivot level (0.359), with support at 0.323 and resistance at 0.395. Overall, the technical outlook suggests a downward trend.
NULL identified. There are no recent news updates, congress trading data, or influential endorsements to act as positive catalysts.
The company's financial performance in Q3 2025 is severely negative, with revenue dropping by -98.82% YoY, net income falling by -472.19% YoY, and EPS declining by -375.00% YoY. Additionally, the stock trend analysis predicts further declines (-1.99% in the next day, -1.3% in the next week, -1.92% in the next month).
In Q3 2025, Sangamo Therapeutics reported a significant deterioration in financial performance. Revenue dropped to $581,000 (-98.82% YoY), net income fell to -$34.93 million (-472.19% YoY), and EPS declined to -$0.11 (-375.00% YoY). The only positive aspect was a stable gross margin of 100%, which did not change YoY.
No recent analyst ratings or price target changes were provided. The lack of updates from analysts indicates limited interest or confidence in the stock.
